Despite these limitations, our results support that germline testing should be offered to all patients with KIT/PDGFRA-wildtype GISTs, regardless of their history of syndromic features, and should target all GIST-associated genes at minimum. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.